[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tinnitus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tinnitus":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,44,0,25,[9,45,70,101,132,152,181,208,268,297,320,340,358,385,420,450,470,495,518,541,564,590,611,635,665],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100652665","phase-2-a-study-of-the-safety-and-efficacy-of-trtl-913-in-healthy-volunteers-part-a-and-in-adults-with-tinnitus-part-b-100652665",false,"NCT07777549","A Study of the Safety and Efficacy of TRTL-913 in Healthy Volunteers (Part A) and in Adults With Tinnitus (Part B)","A Phase 2a, Randomized, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TRTL-913 in Healthy Adult Volunteers Under Fed Conditions (Part A), and an Open-Label Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Efficacy in Adults With Tinnitus (Part B)","Inclusion Criteria:\n\nPart A Inclusion Criteria:\n\n1. Healthy male or female adults aged 18 to 64 years (or 65 to 80 years for an elderly cohort, if enrolled), as determined by the investigator.\n2. Able and willing to provide written informed consent and comply with all study procedures.\n3. Body mass index (BMI) 18.0 to 35.0 kilograms per square meter (kg\u002Fm\\^2) and body weight greater than (\\>) 50 kilogram (kg).\n4. Clinically acceptable medical history, physical examination, vital signs, clinical laboratory tests, and 12-lead ECG, as determined by the investigator.\n5. QT interval corrected using the Fridericia method (QTcF) of less than or equal to (≤) 450 millisecond (msec) for males or ≤470 msec for females.\n6. Nonsmokers or light smokers (\\\u003C10 cigarettes\u002Fweek or equivalent vaping) for at least 3 months before dosing and willing to abstain during confinement.\n7. Women of childbearing potential must have a negative pregnancy test and agree to use highly effective contraception throughout the required study period.\n8. Male participants must agree to use appropriate contraception and refrain from sperm donation for the required study period.\n\nPart B Inclusion Criteria:\n\n1. Male or female adults aged 18 to 64 years.\n2. Able and willing to provide written informed consent and comply with study procedures.\n3. Diagnosis of subjective, stable, chronic, non-pulsatile tinnitus.\n4. Generally healthy aside from tinnitus, with no clinically significant abnormalities on medical history, physical or neurologic examination, vital signs, laboratory tests, or ECG that would interfere with study participation.\n5. BMI 18.0 to 35.0 kg\u002Fm\\^2 and body weight \\>50 kg.\n6. Willing to discontinue prohibited medications and substances before study treatment and throughout study participation.\n7. Women of childbearing potential must have a negative pregnancy test and agree to use highly effective contraception throughout the required study period.\n8. Male participants must agree to use appropriate contraception and refrain from sperm donation for the required study period.\n\nExclusion Criteria:\n\nPart A Exclusion Criteria:\n\n1. Any clinically significant acute or chronic medical condition that, in the investigator's opinion, could affect participant safety or study assessments.\n2. Use of prohibited medications, including moderate or strong cytochrome (CY)P450 inhibitors or inducers, or other prohibited foods or supplements before dosing.\n3. History of seizures, epilepsy, significant head injury associated with loss of consciousness, or other conditions or medications that increase seizure risk.\n4. Clinically significant cardiovascular disease, clinically significant ECG abnormalities, long QT syndrome, torsade de pointes, or a family history of long QT syndrome or sudden cardiac death.\n5. Active infection or clinically significant recent illness before screening or dosing.\n6. Positive test for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.\n7. Clinically significant hepatic or renal impairment or clinically significant laboratory abnormalities.\n8. History of malignancy within the past 10 years (except adequately treated nonmelanoma skin cancer or cervical carcinoma in situ).\n9. Current or recent substance or alcohol use disorder or positive drug or alcohol screening.\n10. Current or history of clinically significant psychiatric illness or suicidal ideation or behavior that would increase study risk.\n11. Pregnant, breastfeeding, or planning pregnancy during the study.\n\nPart B Exclusion Criteria:\n\n1. Current use of, or plans to initiate, pharmacologic or non-pharmacologic treatment for tinnitus during the study.\n2. Regular night-shift work that could interfere with study assessments.\n3. Use of prohibited medications, including moderate or strong CYP450 inhibitors or inducers, or other prohibited foods or supplements before dosing.\n4. History of seizures, epilepsy, significant head injury associated with loss of consciousness, or other conditions or medications that increase seizure risk.\n5. Clinically significant acute or chronic medical condition that, in the investigator's opinion, could affect participant safety or study assessments.\n6. Positive test for HIV, hepatitis B, or hepatitis C.\n7. History of malignancy within the past 10 years (except adequately treated nonmelanoma skin cancer or cervical carcinoma in situ).\n8. Current or recent substance or alcohol use disorder or positive drug or alcohol screening.\n9. Current or history of clinically significant psychiatric illness or suicidal ideation or behavior that would increase study risk.\n10. Pregnant, breastfeeding, or planning pregnancy during the study.",true,"ALL","18 Years","80 Years",{"count":22,"type":23},100,"ESTIMATED","INTERVENTIONAL",[26],"PHASE2","This study will consist of two parts. Double blind Part A will assess the safety, tolerability, and pharmacokinetics of 7 days of dosing in healthy adults, while open label Part B will evaluate the safety, tolerability, and efficacy of a 2-week treatment course in adults with tinnitus.",[29],"Tinnitus",[31,29],"TRTL-913","NOT_YET_RECRUITING","2026-08-17",{"date":35,"type":36},"2026-08-20","ACTUAL",{"date":38,"type":23},"2026-09",{"date":40,"type":23},"2027-08",{"name":42,"class":43},"Tortugas Neuroscience, Inc.","INDUSTRY",1,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":24,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":44},"100652251","efficacy-of-internet-based-cognitive-behavioral-therapy-for-insomnia-in-patients-with-tinnitus-and-insomnia-100652251","NCT07769515","Efficacy of Internet-based Cognitive Behavioral Therapy for Insomnia in Patients With Tinnitus and Insomnia","A Randomized Controlled Trial of Internet-based Cognitive Behavioral Therapy for Insomnia Versus Patient Education in Patients With Tinnitus and Insomnia","Inclusion Criteria:\n\n* Adults aged between 18 and 65 years;\n* Diagnosis of chronic subjective tinnitus persisting for at least 6 months;\n* A score of 38 or higher on the Tinnitus Handicap Inventory (THI);\n* An Insomnia Severity Index (ISI) score of 8 or higher;\n* Ability to understand the study procedures and provide informed consent;\n* Proficiency in reading and writing Chinese;\n* Access to a smartphone for participation in the digital intervention.\n\nExclusion Criteria:\n\n* Objective or pulsatile tinnitus;\n* Specific otologic conditions requiring immediate medical treatment, such as sudden sensorineural hearing loss;\n* Diagnosed organic sleep disorders, such as obstructive sleep apnea;\n* Serious psychiatric disorders, including schizophrenia;\n* Concurrent enrollment in another clinical trial targeting tinnitus or insomnia.","65 Years",{"count":54,"type":23},168,[56],"NA","This single-center, single-blind, randomized controlled trial is designed to evaluate the efficacy of therapist-guided, internet-based cognitive behavioral therapy for insomnia (CBT-I) compared with patient education in patients with chronic subjective tinnitus and clinically significant insomnia. A total of 168 participants will be randomized in a 1:1 ratio to receive either an 8-week internet-based CBT-I intervention or an online patient education intervention. The primary outcome is the between-group mean difference in Tinnitus Handicap Inventory (THI) score at 2 months after randomization. Secondary outcomes include insomnia severity, subjective sleep parameters, tinnitus loudness, anxiety and depression symptoms, and dysfunctional beliefs and attitudes about sleep. Participants will be assessed at baseline, 1 month, 2 months, 3 months, and 5 months.",[29,59],"Insomnia","2026-08-13",{"date":62,"type":36},"2026-08-18",{"date":64,"type":23},"2026-08-24",{"date":66,"type":23},"2029-12-30",{"name":68,"class":69},"Eye & ENT Hospital of Fudan University","OTHER",{"id":71,"slug":72,"hasResults":12,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":24,"phases":80,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":44},"100594327","external-therapy-for-tinnitus-management-100594327","NCT07017998","External Therapy for Tinnitus Management","Mild Therapeutic Hypothermia for Tinnitus Management","Inclusion Criteria:\n\n* Adults 18-55 years of age at the time of signing the informed consent form with primary complaint of tinnitus;\n* Suffering from subjective tinnitus for at least 30 days;\n* Tinnitus whose level of severity is defined by Tinnitus Handicap Inventory (THI) values ≥12,\n* Tinnitus is constant in nature (defined as audible at least 75% of waking hours).\n\nExclusion Criteria:\n\n* Very mild tinnitus (THI values \\\u003C12);\n* Tinnitus that is intermittent in nature;\n* Tinnitus described as non-auditory or pulsatile in nature;\n* Individuals with a history of vertigo or fluctuating hearing loss, such as that related to Menière's disease, chronic otitis, vestibular neuritis, neuroma, otosclerosis cholesteatoma, or temporomandibular joint disorder;\n* Individuals with a history of extreme sensitivity to cold or heat, including individuals with a past history of frostbite or Raynaud's Syndrome.\n* Those who are currently receiving medical, pharmacologic, or therapeutic intervention for tinnitus or other otologic conditions, including sound therapy, cognitive behavioral therapy (CBT), Tinnitus Retraining Therapy (TRT), steroid injections, or other treatments;\n* Those who present with a mental health score indicating significant psychological component, per standard of care, based on PHQ-4 score of moderate to severe anxiety\u002Fdepression.\n* Children (under 18 years), incarcerated individuals, adults unable to consent, and psychologically vulnerable participants.","55 Years",{"count":79,"type":23},80,[56],"The goal of this remote interventional clinical study is to investigate the use of mild therapeutic hypothermia devices for the symptomatic relief of chronic tinnitus. The main aims of the study are:\n\n1. Ascertain the effects of MTH in chronic tinnitus patients using questionnaires measuring tinnitus severity and intervention-related change.\n2. Ascertain the comfort and acceptability of the hypothermia device and therapy.\n\nParticipants with chronic tinnitus will wear the mild therapeutic hypothermia therapy devices for a single 30 minute session. Researchers will compare results from those receiving therapy to those from a control group.",[29,83],"Tinnitus, Subjective",[85,86,87,88,89,90],"tinnitus","ringing in the ears","ringing ears","symptom management","cooling","red light therapy","RECRUITING","2026-07-27",{"date":94,"type":36},"2026-07-28",{"date":96,"type":36},"2025-07-16",{"date":98,"type":23},"2027-12-01",{"name":100,"class":43},"Restorear Devices LLC",{"id":102,"slug":103,"hasResults":12,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":24,"phases":111,"briefSummary":112,"conditions":113,"keywords":114,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":44},"100647689","fr-tavns-tinnitus-tria-100647689","NCT07711639","FR-taVNS Tinnitus Tria","Efficacy of Foot Reflexology and Transcutaneous Auricular Vagus Nerve Stimulation on Tinnitus in Non-Cancer Adult Populations","Inclusion Criteria:\n\n* Age 18-75 years, conscious, able to communicate and comprehend, and able to complete questionnaires and comply with study procedures\n* Tinnitus as the sole chief complaint, with pure-tone thresholds ≤25 dB HL bilaterally at 500, 1000, 2000, and 4000 Hz\n\nExclusion Criteria:\n\n* Objective tinnitus, peripheral vestibular disease, central nervous or cardiovascular causes, or other organic ear pathology\n* Open wounds or skin lesions of the foot or ear, lower-limb edema, history of deep vein thrombosis, or diabetes with most recent HbA1c \\>7.5%\n* Cardiac pacemaker or other implanted electronic device, or other severe cardiovascular disease\n* Foot reflexology or vagus nerve stimulation within the past 3 months\n* Pregnant or breastfeeding women\n* History of epilepsy or seizures\n* Physically frail condition","75 Years",{"count":110,"type":23},180,[56],"Tinnitus is a common neurosensory symptom affecting 12-30% of adults and is closely associated with anxiety, sleep disturbance, and autonomic dysregulation. Current pharmacologic treatments offer limited efficacy and notable side effects, prompting interest in non-pharmacological approaches. This randomized, single-blind, sham-controlled trial evaluates whether foot reflexology (FR), transcutaneous auricular vagus nerve stimulation (ta-VNS), and auricular acupressure (AA) improve tinnitus severity, psychological distress, sleep quality, and autonomic indicators (heart rate variability and salivary cortisol) in non-cancer adults with tinnitus, compared with usual care. Participants are randomized to a foot reflexology group, an auricular vagus nerve stimulation group (each with true and sham subgroups), or a usual-care control group, and are followed at baseline and weeks 2, 4, and 8.",[29],[115,116,117,118,29,119,120,121,122],"Foot Reflexology","Transcutaneous Auricular Vagus Nerve Stimulation","ta-VNS","Auricular Acupressure","Heart Rate Variability","Salivary Cortisol","Sleep Quality","Non-pharmacological intervention","2026-07-23",{"date":125,"type":36},"2026-07-24",{"date":127,"type":36},"2026-04-28",{"date":129,"type":23},"2028-12-31",{"name":131,"class":69},"Tzu Chi University",{"id":133,"slug":134,"hasResults":12,"nctId":135,"briefTitle":136,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":140,"phases":4,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":4},"100647714","clinical-benefit-of-hearing-aid-tinnitus-feature-on-tinnitus-related-annoyance-in-tinnitus-patients-in-belgium-100647714","NCT07711249","Clinical Benefit of Hearing Aid Tinnitus Feature on Tinnitus-Related Annoyance in Tinnitus Patients in Belgium","Inclusion Criteria:\n\n* Participants ≥ 18 years old\n* Participants with chronic tinnitus (≥ 6 months)\n* Participants with the Tinnitus feature activated\n* Participants that have completed the NRS during routine clinical practice and are at least a little bothered by their tinnitus (NRS ≥ 3)\n* Participants with at least one Sonova manufactured hearing aid with the tinnitus feature activated for at least 12 weeks\n\nExclusion Criteria:\n\n\\- Participants reporting pulsatile tinnitus",{"count":139,"type":23},170,"OBSERVATIONAL","Tinnitus, the perception of sound without an external source, affects around 15% of the global adult population (Jarach et al., 2022). For many, tinnitus is a mild annoyance, but a significant subset experiences severe distress, leading to reduced quality of life and increased healthcare burden. Hearing loss is a major risk factor for tinnitus (Biswas et al., 2023), and clinical guidelines recommend hearing aids as a therapeutic option (Langguth et al., 2023). In addition to amplification through hearing aids, sound therapy has long been used to help manage tinnitus (Sereda \\& Hoare, 2024).\n\nA recent randomized controlled trial has demonstrated the clinical efficacy of Sonova hearing aids with integrated noise generator (further referred to as \"Tinnitus-feature\") in reducing tinnitus-related distress. However, the evidence is limited for newer generations of hearing aids and for individuals with severe to profound hearing loss. This study aims to address these gaps by evaluating the clinical benefit of the noise generator feature in newer generations of Sonova hearing aids for adults with tinnitus and hearing loss and in patients with severe to profound hearing loss during routine clinical practice.",[29],"2026-07-14",{"date":145,"type":36},"2026-07-17",{"date":147,"type":23},"2026-07",{"date":149,"type":23},"2026-12",{"name":151,"class":43},"Sonova AG",{"id":153,"slug":154,"hasResults":12,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":159,"targetDuration":4,"studyType":24,"phases":161,"briefSummary":162,"conditions":163,"keywords":164,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":180},"100645946","acupuncture-versus-sham-acupuncture-for-tinnitus-100645946","NCT07700069","Acupuncture Versus Sham Acupuncture for Tinnitus","Efficacy and Safety of Acupuncture Versus Sham Acupuncture in the Treatment of Tinnitus: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n1. Tinnitus as the primary complaint, meeting the diagnostic criteria for subjective idiopathic tinnitus.\n2. Tinnitus duration of at least 6 months.\n3. Patent external auditory canal and intact tympanic membrane.\n4. Bilateral pure tone average no greater than 80 decibels hearing level (dB HL).\n5. No contraindications to MRI or MEG scanning, such as claustrophobia or metallic implants.\n6. Age 18 to 80 years.\n7. Right-handed.\n8. Baseline Tinnitus Handicap Inventory score of 38 or higher.\n9. Able to understand and complete examinations, assessments, and treatment procedures under physician guidance.\n10. Willing to participate and able to provide written informed consent before treatment.\n\nExclusion Criteria:\n\n1. Inner ear or auditory nerve disorders, including sudden sensorineural hearing loss, Meniere disease, otosclerosis, or acoustic neuroma.\n2. External or middle ear diseases, including otitis externa, foreign body in the external auditory canal, eczema of the external auditory canal, cerumen impaction, acute or chronic otitis media with effusion, or acute or chronic suppurative otitis media.\n3. Non-otogenic tinnitus caused by acute or chronic systemic diseases involving hematologic, endocrine, renal, or other major organ systems.\n4. Objective tinnitus, including myogenic, vascular, or patulous eustachian tube-related tinnitus.\n5. Cognitive impairment or tinnitus caused by other neurological diseases, including stroke, epilepsy, traumatic brain injury, severe headache history, severe central ischemia, brain tumor, neurasthenia, or post-neurosurgical tinnitus.\n6. Severe cardiovascular or cerebrovascular disease, intracranial space-occupying disease, tumor, or severe pulmonary, hepatic, renal, or hematopoietic disease.\n7. Pregnancy or lactation.\n8. Psychiatric disease, impaired consciousness, or inability to cooperate with examinations or treatment.\n9. Participation in another conflicting clinical trial within 6 months before enrollment or currently participating in another conflicting clinical trial.",{"count":160,"type":23},226,[56],"This multicenter, randomized, sham-controlled clinical trial will evaluate the efficacy and safety of acupuncture for patients with subjective idiopathic tinnitus. A total of 226 eligible participants will be randomly assigned to receive either acupuncture or sham acupuncture. Both groups will receive treatment for 5 weeks. The primary outcome is the change in Tinnitus Handicap Inventory score from baseline to Week 5. Secondary outcomes include tinnitus loudness, tinnitus severity, sleep quality, anxiety, depression, audiological assessments, and adverse events. Exploratory neuroimaging outcomes include functional magnetic resonance imaging and magnetoencephalography measures.",[29],[165,166,167,168,169,170],"Subjective Idiopathic Tinnitus","Acupuncture","Sham Acupuncture","Randomized Controlled Trial","Tinnitus Handicap Inventory","Magnetoencephalography","2026-07-07",{"date":173,"type":36},"2026-07-13",{"date":175,"type":23},"2026-07-10",{"date":177,"type":23},"2027-03-31",{"name":179,"class":69},"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University",3,{"id":182,"slug":183,"hasResults":12,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":24,"phases":190,"briefSummary":191,"conditions":192,"keywords":193,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":44},"100598437","noninvasive-therapy-for-tinnitus-100598437","NCT07071480","Noninvasive Therapy for Tinnitus","Noninvasive Therapeutic Hypothermia for Tinnitus","Inclusion Criteria:\n\n* Adults aged 18 years or older at the time of signing the consent form\n* Fluency in English or Spanish\n* Chronic subjective tinnitus for more than 30 days defined as audible at least 75% of waking hours\n* At least mild tinnitus, score ≥18 on the Tinnitus Handicap Inventory (THI)\n\nExclusion Criteria:\n\n* Severe anxiety, score ≥ 15 on the Generalized Anxiety Disorder-7 (GAD-7)\n* Tinnitus described as non-auditory or pulsatile in nature\n* Catastrophic tinnitus, score ≥78 on the THI\n* Tinnitus that is intermittent in nature\n* Abnormal tympanometric findings\n* Presence of conductive component as characterized by air-bone gaps ≥15 dB at two or more consecutive frequencies\n* Otologic pathologies (including, but not limited to): acoustic neuroma\u002F vestibular schwannoma, chronic ear disease, Meniere's disease, documented fluctuating hearing loss, or ototoxicity\n* Temporomandibular joint disorder\n* Those who are currently receiving medical, pharmacologic, or therapeutic intervention for tinnitus or other otologic conditions.\n* Active hearing aid use\n* Dizziness at the time of signing the consent form or at the time of starting the study protocol treatment\n* Adults unable to consent\n* Individuals who are not yet adults (infants, children, teenagers)\n* Pregnant women\n* Prisoners",{"count":189,"type":23},40,[56],"The goal of this interventional clinical study is to establish mild therapeutic hypothermia, delivered non-invasively to the structures of the inner ear, as a safe and repeatable therapeutic method for symptomatic relief of tinnitus. The study will assess both objective and subjective measures to address two main aims:\n\n1. Ascertain the benefits of mild therapeutic hypothermia for symptomatic relief of chronic tinnitus in participants using the ReBound hypothermia device.\n2. Ascertain the benefits of mild therapeutic hypothermia for symptom management in chronic tinnitus participants over six months using the ReBound device.\n\nParticipants will wear the ReBound hypothermia device for 30 minutes in a single session. Researchers will compare results from those receiving the therapy to those from a control group (sham therapy). Participants will also use the device in-home for 6 months and monitor their symptoms with online surveys.",[29,83],[85,194,86,195,196,197,198,88,199,200],"ringing","subjective tinnitus","constant tinnitus","treatment","symptom reduction","tinnitus management","intervention",{"date":202,"type":36},"2026-07-09",{"date":204,"type":36},"2025-11-24",{"date":206,"type":23},"2027-05-31",{"name":100,"class":43},{"id":209,"slug":210,"hasResults":12,"nctId":211,"briefTitle":212,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":24,"phases":215,"briefSummary":217,"conditions":218,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":4},"100611443","phase-4-emerging-indications-for-hyperbaric-oxygen-treatment-100611443","NCT07240649","Emerging Indications for Hyperbaric Oxygen Treatment","Inclusion Criteria:\n\n* Patients referred for HBOT with an emerging indication\n\nExclusion Criteria:\n\n* Contraindication to hyperbaric oxygen treatment (untreated seizures, pneumothorax, significant pulmonary airspace pathology that might lead to pulmonary barotrauma, unmanageable confinement anxiety, chronic obstructive pulmonary disease with CO2 retention)\n* Pregnant persons",{"count":22,"type":23},[216],"PHASE4","This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially benefit from HBOT) using the Multicenter Registry for Hyperbaric Oxygen Treatment. The study team aims to collect ongoing data on how well HBOT treats these emerging indications, and to add these data to the growing HBO Registry. The research team hypothesizes that HBOT will result in improvements of the condition of the various emerging indications.",[219,220,221,222,223,224,225,226,227,228,229,230,231,232,233,234,235,236,237,238,239,240,241,242,243,29,244,245,246,247,248,249,250,251,252,253,254,255,256,257,258],"Post-COVID-19 Condition","Ulcerative Colitis","Crohn Disease","Calciphylaxis","Frostbite","Acute COVID-19","Pyoderma Gangrenosum","Pterygium","Hypospadias","Head Trauma","Pneumatosis Intestinalis","Ischemic Bowel","Raynaud Syndrome","Malignant Otitis Externa","Nonarteritic Anterior Ischemic Optic Neuropathy","Central Retinal Vein Occlusion","Femoral Head Necrosis","Invasive Fungal Infection","Chronic Anal Fissure","Vasculitic Ulcer","Graft-vs-Host Disease","Decubitus Ulcer","Greater Trochanteric Pain Syndrome","Rectovaginal Fistula","Pouchitis","Clostridium Enterocolitis","Branch Retinal Artery Occlusion","Axonotmesis","Multiple Sclerosis","Inclusion Body Myositis","Epidermolysis Bullosa (EB)","Osteonecrosis","Ulcer Ischemic","Avascular Necrosis of Bone","Prosthesis Related Infections","Facial Filler Injections","Cystitis Chronic","Ligament Injury","Anastomosis, Leaking","Cartilage Injury","2026-07-02",{"date":261,"type":36},"2026-07-06",{"date":263,"type":23},"2026-08",{"date":265,"type":23},"2035-12",{"name":267,"class":69},"Jay C. Buckey Jr.",{"id":269,"slug":270,"hasResults":12,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":274,"eligibilityCriteria":275,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":276,"targetDuration":4,"studyType":24,"phases":278,"briefSummary":279,"conditions":280,"keywords":284,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":293,"leadSponsor":295,"locationsCount":4},"100641779","phase-4-comparing-migraine-preventive-therapies-vs-anti-cgrp-therapies-for-tinnitus-in-patients-with-migraine-compact-pm-100641779","NCT07655440","Comparing Migraine Preventive Therapies vs. Anti-CGRP Therapies for Tinnitus in Patients With Migraine (COMPACT-PM)","Comparative Outcomes of Migraine Preventives and Anti-CGRP Therapies for Tinnitus in Patients With Migraine: A Randomized Active-Comparator Controlled Trial (COMPACT-PM)","COMPACT-PM","Inclusion Criteria:\n\n* Age 18 years or older\n* Non-pulsatile, subjective tinnitus present for at least 6 months\n* Tinnitus Functional Index (TFI) score greater than 25 at screening, indicating at least mild-to-moderate tinnitus burden\n* Current or past history of migraine, vestibular migraine, or episodic headache disorder, diagnosed by a physician or meeting ICHD-3 criteria\n* Clinically appropriate candidate for migraine preventive therapy as determined by the treating clinician\n* Stable medication regimen for at least 3 months prior to enrollment (no new medications started or stopped within 3 months of screening)\n* Ability to provide written informed consent\n* Ability to complete self-report questionnaires in English or with certified interpreter assistance\n* Willingness to attend three in-person study visits over 24 weeks and complete daily symptom diaries\n\nExclusion Criteria:\n\n* Pulsatile tinnitus or objective tinnitus (tinnitus audible to examiner)\n* Pregnancy, planned pregnancy during the study period, or breastfeeding\n* Participation in any other interventional tinnitus treatment research protocol during the study period\n* Currently receiving a CGRP-targeting medication (for participants being considered for the conventional arm) or a conventional migraine preventive medication listed in this protocol (for participants being considered for the CGRP arm) - to avoid within-arm ineligibility at randomization\n* Known contraindication to all medications within the assigned study arm\n* History of serious cardiovascular event (myocardial infarction, stroke, or unstable angina) within 6 months of enrollment\n* Severe hepatic or renal impairment that would contraindicate study medications\n* Active psychiatric disorder requiring medication adjustment within 3 months of enrollment\n* Known hypersensitivity or prior serious adverse reaction to a medication within the assigned study arm\n* Active malignancy or life expectancy less than 12 months\n* Inability to complete study procedures or follow-up visits in the judgment of the investigator",{"count":277,"type":23},120,[216],"Many people with migraine also experience tinnitus - a persistent ringing, buzzing, or hissing in the ears - and research suggests these conditions share underlying biological mechanisms, including a protein called calcitonin gene-related peptide (CGRP) that is active in both the brain and the inner ear. COMPACT-PM is a randomized trial comparing two classes of migraine preventive medications in adults with bothersome tinnitus and a history of migraine: anti-CGRP therapies (newer injectable or oral agents that block CGRP or its receptor) versus conventional migraine preventives (antidepressants including amitriptyline, nortriptyline, and venlafaxine; antihypertensives including propranolol, verapamil, and candesartan; and the anticonvulsant topiramate). Participants are randomly assigned - like a coin flip - to one of the two treatment groups; neither group receives a placebo, as both receive active migraine treatment. The study's primary outcome is change in the Tinnitus Functional Index (TFI) over 24 weeks, with additional measures including hearing tests, balance assessments, auditory brainstem response testing, and a comprehensive symptom diary. The study is conducted at the Stanford Ear Institute and is funded by a philanthropic gift to the Department of Otolaryngology - Head \\& Neck Surgery at Stanford University.",[281,29,282,283],"Migraine Associated Vertigo","Migraine","Vestibular Migraine",[85,285,286,287,288],"migraine","vestibular migraine","migraine-associated tinnitus","CGRP","2026-06-15",{"date":291,"type":36},"2026-06-17",{"date":147,"type":23},{"date":294,"type":23},"2031-07",{"name":296,"class":69},"Stanford University",{"id":298,"slug":299,"hasResults":12,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":303,"eligibilityCriteria":304,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":305,"enrollmentInfo":306,"targetDuration":4,"studyType":24,"phases":308,"briefSummary":309,"conditions":310,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":4},"100643000","efficacy-of-a-tinnitus-implant-for-people-with-severe-tinnitus-without-damaging-the-acoustic-hearing-100643000","NCT07648615","Efficacy of a Tinnitus Implant for People With Severe Tinnitus Without Damaging the Acoustic Hearing.","Extracochlear Electrical Stimulation in Patients With Intractable Tinnitus - a Feasibility Study","EESPIT","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Proficient in written and spoken Dutch, defined by self-report or the researcher\n* Intractable severe\u002Funcompensated unilateral tinnitus, evaluated by VAS-score, and confirmed by Tinnitus functionality Index (TFI) and Tinnitus Questionnaire (TQ) (global TFI score of 54 and above and global TQ-score of 47 and above)\n* Suffering from tinnitus for at least a year\n* Not responsive to the normally available clinical tinnitus treatment.\n* High-frequency sensorineural hearing loss in the ear to be treated\n* Hearing aid did not provide any tinnitus suppression\n* Ability to use the device and follow a personalized rehabilitation program.\n* Ability to undergo the surgery\n\nExclusion Criteria:\n\n* Chronic middle ear pathology\n* Surgical anatomy not allowing for implantation, evaluated by CBCT\u002FMRI imaging\n* Tinnitus suppression is possible to achieve with hearing aids (as per self-report\u002Fdocumentation)\n* Clinically significant depression (HADS-score of 11 and above)\n* Active treatment, or treatment in the past 6 months, with either a chemotherapeutic drug for cancer, or radiation therapy to the head or neck region\n* Pregnant or breastfeeding women\n* Current participation in another interventional clinical study\u002Ftrial in the past 30 days involving an investigational drug or device.\n* Medical contra-indications to middle ear surgery, and\u002For anesthesia\n* Cholesteatoma in the ear to be treated","110 Years",{"count":307,"type":23},6,[56],"This is a prospective, intervention-based, non-randomized, pre-post, single-site feasibility study that will involve data collection from individuals with intractable tinnitus. The study comprises a screening under local anesthesia and a surgery to implant the medical device. The screening will allow for accurate selection of patients. For patients not fulfilling the criteria for chronic extracochlear stimulation, the study will stop there. Patients eligible for chronic stimulation will undergo a second surgery under general anaesthesia involving the implantation of a cochlear implant with an electrode placed outside the cochlea in the vicinity of the round window. Each surgical procedure will be followed by a series of medical check-ups. Following implantation, the safety and efficiency of extracochlear chronic stimulation will be evaluated as well as the tinnitus suppression and speech perception.",[29],"2026-06-11",{"date":289,"type":36},{"date":314,"type":23},"2026-09-01",{"date":316,"type":23},"2028-09-01",{"name":318,"class":319},"ENTIC research and training centre of the European Institute for ORL","NETWORK",{"id":321,"slug":322,"hasResults":12,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":4,"eligibilityCriteria":326,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":52,"enrollmentInfo":327,"targetDuration":4,"studyType":24,"phases":328,"briefSummary":329,"conditions":330,"keywords":331,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":335,"completionDateStruct":336,"leadSponsor":338,"locationsCount":44},"100632576","manual-acupuncture-for-acute-primary-tinnitus-100632576","NCT07515482","Manual Acupuncture for Acute Primary Tinnitus","Manual Acupuncture Versus Sham Acupuncture and Usual Care for Acute Primary Tinnitus: Multicentre, Randomized Clinical Trial","Inclusion Criteria:\n\n1. Aged 18-65 years, male or female;\n2. Primary complaint is persistent tinnitus (unilateral or bilateral);\n3. Meet the diagnostic criteria for primary tinnitus according to the 2014 Clinical Practice Guideline developed by the American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF);\n4. Had continuous tinnitus ≥2 weeks and \\\u003C6 months;\n5. Tinnitus should be bothersome, with a screening THI score 28-76;\n6. Acupuncture naive;\n7. Able to provide written informed consent.\n\nExclusion Criteria:\n\n1. Objective tinnitus;\n2. Pulsatile tinnitus;\n3. Diagnosed as secondary tinnitus as evaluated by audiologists and clinicians(Menière's disease, temporomandibular joint disorder or other diseases);\n4. Had evidence of conductive hearing loss (confirmed by abnormal otoscopy or tympanogram);\n5. Had contraindications for acupuncture, including curent pregnant, severe anemia, coagulation disorders, etc;\n6. Having difficulties in expressing their symptoms clearly( severe mental disorders or cognitive impairment);\n7. Currently suffering from other serious acute or chronic organic diseases, such as cerebrovascular, cardiovascular, liver, kidney, hematological diseases, infectious diseases, or malignant tumors;\n8. Has received intratympanic injection, postauricular injection, corticosteroids, or other medications for tinnitus treatment (includingTraditional Chinese Medicine or proprietary Chinese medicines) within the past 2 weeks or at baseline;\n9. Participated in other clinical trials, particularly those closely related to tinnitus treatment, such as sound therapy;\n10. have a strong desire for medication treatment.",{"count":110,"type":23},[56],"This clinical trial aims to assess the efficacy of manual acupuncture for patients with acute primary tinnitus.",[29],[29,332],"acupuncture","2026-06-10",{"date":311,"type":36},{"date":289,"type":23},{"date":337,"type":23},"2027-12-12",{"name":339,"class":69},"Dan Bing",{"id":341,"slug":342,"hasResults":12,"nctId":343,"briefTitle":344,"officialTitle":344,"acronym":4,"eligibilityCriteria":345,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":346,"targetDuration":4,"studyType":24,"phases":347,"briefSummary":348,"conditions":349,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":44},"100325038","acoustic-and-electrical-stimulation-for-the-treatment-of-tinnitus-100325038","NCT03511807","Acoustic and Electrical Stimulation for the Treatment of Tinnitus","Inclusion Criteria:\n\n1. 18 years or older\n2. Male or female\n3. Tinnitus present for 6 months or more\n4. Adequate command of English to reliably describe the unusual sensory percepts provided by electrical stimulation, and to complete surveys.\n5. For patients undergoing electrical stimulation via a cochlear implant, they should have a cochlear implant prior to enrollment (not applicable for acoustic stimulation)\n\nExclusion Criteria:\n\n1. Aged less than 18 years\n2. Active illicit drug use, alcohol dependence\n3. Treatable cause of tinnitus\n4. History of psychosis\n5. Abnormalities of the ear canal or ear drum\n6. Chronic middle ear disease\n7. Subjects on medications known to cause tinnitus (aspirin, ibuprofen, naproxen) which could not be stopped will be excluded.\n8. Pregnant or breastfeeding.",{"count":22,"type":23},[56],"Tinnitus, or ringing in the ears, affects 10% to 30% of the population. Of those, 20% have tinnitus bothersome enough to seek medical attention. In many people, tinnitus can significantly affect the quality of life. At this point in time, there is no effective treatment or cure available for tinnitus.\n\nIt has been found that electrical stimulation of the inner ear can reduce and in some cases eliminate tinnitus. The purpose of this research is to investigate both acoustic and electrical stimulation of the inner ear as a possible treatment of tinnitus.\n\nIn both acoustic and electrical testing conditions, the subjects will be instructed to be familiar with a 0-10 ranking scale of loudness. In acoustic testing, the stimulus will be presented through headphones in a noiseless environment, and the subject will be asked to report on the loudness of the presented sound and the level of the tinnitus at 20-second intervals. If the subject cannot perceive the presence of the tinnitus, a value of zero will be assigned. A typical sound will be presented for 3 to 6 minutes. Loudness will be reported for 1 to 4 minutes after stimulus offset to measure the presence and duration of residual inhibition.\n\nElectrical stimulation will be delivered to the inner ear in three ways, 1. using a cochlear implant (implant placed in the inner ear to replace hearing function), 2. Using an electrode placed in the ear canal, and 3. using a small needle inserted through the ear drum. Various electrical signals will be used to evaluate the reduction in the tinnitus perception by the subject. The subjects will rate the loudness of the tinnitus before, during, and after the electrical signal. Surveys will be used to evaluate the tinnitus loudness and the quality of life of the subjects. Hearing tests will be used before and after the procedures. The long term goal of this research is to develop a device to treat tinnitus in people who can hear and to develop programs for cochlear implants that help treat tinnitus in deaf people.",[29],"2026-06-09",{"date":311,"type":36},{"date":353,"type":36},"2017-01-01",{"date":355,"type":23},"2032-11",{"name":357,"class":69},"University of California, Irvine",{"id":359,"slug":360,"hasResults":12,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":364,"eligibilityCriteria":365,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":366,"targetDuration":4,"studyType":24,"phases":368,"briefSummary":369,"conditions":370,"keywords":373,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":384},"100565424","evaluating-how-a-tinnitus-implant-affects-tinnitus-loudness-in-adults-with-chronic-tinnitus-and-varying-levels-of-hearing-loss-100565424","NCT06641999","Evaluating How a Tinnitus Implant Affects Tinnitus Loudness in Adults With Chronic Tinnitus and Varying Levels of Hearing Loss","A Prospective, Multicentric, Feasibility Investigation to Assess the Effect of the Tinnitus Implant on Tinnitus Loudness in Adults With Moderate to Severe Chronic Tinnitus Accompanied by Normal Hearing to Moderately Severe Hearing Loss.","TINIS","Inclusion criteria\n\n* 18 years or older.\n* Normal hearing to moderately severe sensorineural hearing loss defined as a pure tone average (PTA) at 500, 1000, 2000 and 4000 Hz less than 65 dB HL in both ears (separately) and best-aided phoneme recognition score more than or equal to 80% in both ears (separately).\n* Unilateral or asymmetric subjective (no pulsatile) tinnitus. In case of asymmetric tinnitus, the worst ear must be implanted.\n* Tinnitus duration of at least 6 months.\n* Severe tinnitus loudness determined by a. VAS-L score in the severe range i.e. 50-100\u002F100 b. TFI score in the severe range i.e. 52-90\u002F100\n* Tinnitus that is intractable and has not been ameliorated satisfactorily by standard of care such as CBT or hearing aid, when such interventions are potentially clinically indicated.\n* Clinically significant reduction in VAS-L score (≥ 15\u002F100 points) in response to trans-tympanic promontory stimulation\n* Willing and able to provide written informed consent.\n* Medically able to use the device and to undergo general anaesthesia for implantation taking into account their medical condition, contraindications and surgical risks.\n* Dutch language proficiency\n\nExclusion Criteria:\n\n* Pulsatile tinnitus.\n* Any anatomical or structural abnormalities of the inner ear, cochlear nerve, or brainstem that would negatively impact response to study intervention (determined in a temporal bone CT and if necessary (e.g. possibility of vestibular\u002Facoustic schwannoma) by a MRI scan of the head (of sufficient quality at the discretion of the investigator) not more than five years old at the time of enrolment\n* Medical contraindications limiting correct placement, activation, or treatment (determined by medical history; contraindications include brain or major ear surgery, brain or temporal bone tumor(s), recurrent ear infections within the last year, otosclerosis, prior major head trauma that results in sudden injury that causes damage to the brain and results in lasting cognitive impairment).\n* Any medical condition, including mental illness or substance abuse, deemed by the Investigator to likely interfere with a patient's ability to sign informed consent, cooperate and\u002For participate in the study, or interfere with the interpretation of the results (incl. pregnant or breastfeeding women or patients with unrealistic expectations).\n* Presence of clinically diagnosed depression or anxiety determined by a psychological state evaluation (if PHQ-9 \\> 9 or GAD-7 \\> 9).\n* Active (currently or within two months prior to enrolment) use of medications (taking regularly scheduled antidepressant, anxiolytic, antipsychotic or antiepileptic medications, or other neuromodulator agents) or other tinnitus treatments.\n* It is permissible to include people who use such medications at lower doses as a sleep aid or for people who intermittently use such medications for situational anxiety (e.g., Ativan before airplane travel). A change in medication during the trial should be avoided.\n* It is permissible to include people who prefer to use a hearing aid to amplify ipsilateral hearing loss. The start of using a hearing aid during the trial should be avoided.\n* Investigator site personnel directly affiliated with this study and\u002For their immediate families; immediate family is defined as a spouse, parent, child, or sibling.\n* Cochlear employees or employees of Contract Research Organizations or contractors engaged by Cochlear for the purposes of this investigation.\n* Current participation, or participation in another interventional clinical study\u002Ftrial in the past 60 days, involving an investigational drug or device (unless the other investigation was\u002Fis a Cochlear sponsored investigation and determined by the investigator or Sponsor to not impact this investigation).",{"count":367,"type":23},16,[56],"This study will test an experimental Tinnitus Implant System that consists of a cochlear implant, sound processor and programming software. The Tinnitus implant is surgically placed under the skin just behind the ear in the mastoid bone. It has an electrode that extends from the implant into the promontory bone of the cochlea which emits electrical signals that stimulate the auditory nerve. The sound processor is worn behind the ear and powers the implant via the coil. The study will be conducted in adults with moderate to severe chronic tinnitus who have normal hearing to moderately severe hearing loss in the inner ear. The study participants will undergo a series of tests that include evaluations of tinnitus loudness and annoyance, and self-reported questionnaires on their tinnitus and general health.",[29,371,372],"Hearing Loss, Bilateral or Unilateral","Normal Hearing",[85,374],"cochlear implant","2026-06-01",{"date":377,"type":36},"2026-06-02",{"date":379,"type":36},"2025-06-16",{"date":381,"type":23},"2027-07",{"name":383,"class":43},"Cochlear",2,{"id":386,"slug":387,"hasResults":12,"nctId":388,"briefTitle":389,"officialTitle":390,"acronym":391,"eligibilityCriteria":392,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":393,"enrollmentInfo":394,"targetDuration":4,"studyType":24,"phases":396,"briefSummary":397,"conditions":398,"keywords":402,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":180},"100637338","maximizing-quality-of-life-after-cancer-through-rehabilitation-100637338","NCT07622407","Maximizing Quality of Life After Cancer Through Rehabilitation","A Transdisciplinary Interventions to MaximizE QuaLitY of Life After Cancer Through REHABilitation (TIMELY REHAB)","TIMELY REHAB","Inclusion Criteria:\n\nParticipants must be:\n\n* diagnosed with head and neck malignancy within the past 60 days;\n* prescribed a treatment plan at participating site that includes at least 1 dose of a cisplatin-based chemotherapy, or at least one dose of radiotherapy and\u002For surgery;\n* prescribed Intensive Dysphagia Therapy (IDT) at the participating site;\n* sufficient fluency in written English to be able to complete the study patient reported outcome questionnaires.\n\nExclusion Criteria:\n\nParticipants will be excluded is they have:\n\n* distant metastasis at enrollment;\n* diagnosis of second primary non-head and neck cancer in the thorax or the central nervous system at enrollment;\n* prior or planned total laryngectomy;\n* prior or planned cochlear implant;\n* head and neck radiotherapy for thyroid or cutaneous\u002Fskin primary tumors, regardless of neck fields;\n* cognitively or physically unable to participate (patient, physician or nurse report patient is incapable of participating), medical records indicate that participant exhibits aggressive behavior, participant has documented dementia, Alzheimer's disease, or severe psychosocial disorder, or notes indicate an individual is not legally capable of providing informed consent (participant has a legal guardian);\n* moderate\u002Fsevere dysphagia at enrollment per baseline videofluoroscopy DIGEST grade \\>=2;\n* severe\u002Fprofound hearing loss at enrollment per baseline audiogram;\n* exhibits Meniere's disease or retrocochlear disorder based on baseline hearing test results, patient report or notes in electronic medical records;\n* exhibits active or recent history of middle ear disorder based on otoscopy, tympanometry, baseline hearing test results, patient report, or medical record documentation;\n* unwilling to participate.","89 Years",{"count":395,"type":23},74,[56],"Treatment for head and neck cancer (HNC) often includes cisplatin chemotherapy and radiation. This treatment causes hearing loss and trouble swallowing in 70% of patients. If untreated, these symptoms increase stress and lower quality of life for survivors. Veterans with HNC usually get help for swallowing. However, damage to the hearing and balance systems-known as ototoxicity-is often missed or only addressed when it becomes very severe. To fill this gap, the investigators plan a clinical trial at two VA sites. The investigators compare the usual swallowing therapy alone to a new, more comprehensive program. This new program includes:\n\n1. the standard swallowing therapy,\n2. proactive management to protect hearing and balance or manage problems that can't be prevented, and\n3. other rehabilitation services based on a tele-oncology nurse's assessment. The hearing and balance intervention features quick screening tests and validated questionnaires to identify early signs of damage. These are given during cancer or radiation treatment visits to maximize convenience for the patient. Audiologists review these results remotely using tele-health technology. The investigators will also use new tools to predict and spot hearing problems that are personalized for each patient. The audiologist works closely with the patient and the care team to arrange further help if needed.\n\nThe tele-oncology nurse checks for other rehabilitation needs using a screening tool validated in Veterans, shares this information with the team, and advises patients about recommended care.\n\nThe investigators expect the results to show that managing hearing loss with swallowing therapy while improving care coordination for rehabilitation reduces survivors' stress and improves well-being compared to swallowing therapy alone.",[399,400,29,401],"Head and Neck Cancer","Hearing Loss","Dysphagia",[403,404,405,406,399,407,401,408,409,29],"Audiology","Chemotherapy","Cisplatin","Drug-related side effects and adverse reactions","Ototoxicity","Professional practice gaps","Sensorineural hearing loss","2026-05-27",{"date":412,"type":36},"2026-06-03",{"date":414,"type":23},"2027-03-01",{"date":416,"type":23},"2030-06-30",{"name":418,"class":419},"VA Office of Research and Development","FED",{"id":421,"slug":422,"hasResults":12,"nctId":423,"briefTitle":424,"officialTitle":425,"acronym":4,"eligibilityCriteria":426,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":427,"targetDuration":429,"studyType":140,"phases":4,"briefSummary":430,"conditions":431,"keywords":433,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":448,"locationsCount":44},"100641014","ai-assisted-diagnosis-triage-and-assessment-of-hearing-loss-and-tinnitus-100641014","NCT07586098","AI-assisted Diagnosis, Triage and Assessment of Hearing Loss and Tinnitus","Artificial Intelligence for the Automated Diagnosis, Triage, and Assessment of Patients With Hearing Loss and Tinnitus: A Pilot Comparative Study With Clinical Evaluation by Otolaryngologists","Inclusion Criteria:\n\n* Patients assessed in the RCHT virtual hearing loss and tinnitus clinic.\n* Presenting symptoms of hearing loss and\u002For tinnitus.\n* Ability to provide informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Individuals under 18 years of age.\n* Patients unable to provide informed consent.\n* Patients without sufficient English proficiency where translation services cannot be arranged.\n* Cases where data quality is insufficient for analysis.",{"count":428,"type":23},1500,"1 Year","Hearing loss affects approximately 11 million people in the UK, while tinnitus impacts around 7 million. Both conditions can significantly reduce quality of life and are linked to poorer mental health and employment challenges. Each year, tinnitus alone accounts for more than one million GP appointments, and patients referred to hospital ear, nose and throat (ENT) services often face long delays, sometimes exceeding a year, before their first assessment.\n\nTo address this demand, the Royal Cornwall Hospitals NHS Trust has developed a virtual ENT clinic. Patients undergo a validated hearing test in person and complete online questionnaires. Clinicians then review these data to determine next steps, which may include discharge with advice, referral for imaging, or a face-to-face consultation. Initial trials demonstrated that the majority of patients could be managed virtually, substantially reducing waiting times. However, clinicians must still review every case, limiting capacity for patients who require direct care.\n\nThis project builds on the virtual clinic by introducing artificial intelligence (AI) to support the assessment process. Using explainable AI methods, the system will be trained to replicate clinician-level decision-making while providing transparent reasoning for its recommendations. The study will evaluate how closely AI-generated outcomes align with clinician assessments, with all cases continuing to receive a clinician's final review. Clinicians will not be aware of the recommendations produced by the AI tool, but the study aims to measure how concordant AI recommendations are with clinician assessments.\n\nIf the AI tool's clinical recommendations closely align with clinician recommendations (the gold standard for care), the AI tool could be introduced as a clinical recommendation assistant tool, streamlining the triage and management of hearing loss and tinnitus, enabling clinicians to focus on complex cases, accelerating access to care, and improving efficiency.",[432,29],"Hearing Loss, Adult-Onset",[434,400,29,435,436,437,438,439,440],"Artificial Intelligence","Clinical Decision Support Systems","Computerized","Telemedicine","Otolaryngology","Patient Satisfaction","Feasibility Studies","2026-05-07",{"date":443,"type":36},"2026-05-14",{"date":445,"type":23},"2026-05-30",{"date":447,"type":23},"2027-08-31",{"name":449,"class":69},"Royal Cornwall Hospitals Trust",{"id":451,"slug":452,"hasResults":12,"nctId":453,"briefTitle":454,"officialTitle":455,"acronym":4,"eligibilityCriteria":456,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":457,"enrollmentInfo":458,"targetDuration":4,"studyType":24,"phases":460,"briefSummary":461,"conditions":462,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":465,"completionDateStruct":467,"leadSponsor":469,"locationsCount":44},"100635911","fudan-tinnitus-doctor-for-tinnitus-management-100635911","NCT07558837","Fudan Tinnitus Doctor for Tinnitus Management","A Multi-agent Large Language Model Conversational AI for Tinnitus Management: The Fudan Tinnitus Doctor Randomized Controlled Trial","Inclusion Criteria:\n\n1. Diagnosis of subjective tinnitus confirmed by a qualified investigator.\n2. Tinnitus duration ≥ 3 month prior to screening.\n3. THI score of ≥ 18\n4. Aged between 18 and 70 years\n5. The ability to use a smartphone: Both groups will receive therapeutic support and disease management primarily through a mobile application or web-based platform. This requires functional ability to operate the provided software and willingness to engage with the digital intervention protocol.\n6. Perceptibility: Tinnitus is present and recognizable by the participant under ordinary daily conditions (not only in quiet environments).\n7. Compliance and consent: Participant is assessed by the Investigator as able to understand study procedures, voluntarily agrees to participate, is willing to comply with all trial-related requirements, and provides signed informed consent prior to performance of any protocol-specified procedure.\n\nExclusion Criteria:\n\n1. Acute-phase tinnitus (duration \\\u003C 3 month or tinnitus secondary to acute otologic events).\n2. Pulsatile or objective tinnitus.\n3. Unstable symptoms: Fluctuating tinnitus loudness at screening or baseline.\n4. Psychiatric contraindication: History or current presence of severe psychiatric disorders (e.g., major depressive disorder with recent suicidality, schizophrenia) that, in the opinion of the Investigator, may interfere with study participation or data validity.\n5. Testing limitations: Inability to adequately complete tinnitus testing procedures or comply with study assessments.\n6. Prior therapy exposure: Previous history of sound therapy specifically for tinnitus management.\n7. Concurrent treatments: Ongoing psychotherapy for conditions such as anxiety or depression, or any other psychological treatment that may interfere with the study endpoints.\n8. Concurrent trial participation: Active participation in another interventional research study that, in the opinion of the Investigator, could affect tinnitus symptoms or interact with study procedures.\n9. Investigator judgment: Any condition (medical, surgical, psychiatric, or social) or factor which, in the Investigator's judgment, renders the subject unsuitable for participation, places the patient at higher risk, or may interfere with compliance or scientific validity of the trial.","70 Years",{"count":459,"type":23},256,[56],"The goal of this clinical trial is to evaluate whether a conversational artificial intelligence-based digital intervention can improve symptoms in adults with chronic subjective tinnitus.\n\nThe main questions it aims to answer are:\n\nDoes the Fudan Tinnitus Doctor (FTD) system reduce tinnitus severity as measured by the Tinnitus Handicap Inventory (THI).\n\nDoes the FTD system improve sleep quality, anxiety, depression, and overall patient-reported outcomes.\n\nResearchers will compare the FTD system to a non-conversational digital education program to determine whether the AI-based intervention provides greater clinical benefits.\n\nParticipants will:\n\nUse either the FTD conversational AI system or a static digital education program for 30 days.\n\nComplete standardized questionnaires assessing tinnitus severity, sleep, mood, and overall improvement at baseline, Day 14, and Day 30.\n\nEngage with the digital platform for tinnitus self-management.",[29],"2026-05-04",{"date":441,"type":36},{"date":466,"type":23},"2026-05-01",{"date":468,"type":23},"2027-05-30",{"name":68,"class":69},{"id":471,"slug":472,"hasResults":12,"nctId":473,"briefTitle":474,"officialTitle":475,"acronym":4,"eligibilityCriteria":476,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":477,"enrollmentInfo":478,"targetDuration":4,"studyType":24,"phases":480,"briefSummary":481,"conditions":482,"keywords":484,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":486,"lastUpdatePostDateStruct":487,"startDateStruct":489,"completionDateStruct":491,"leadSponsor":493,"locationsCount":4},"100633121","efficacy-of-acupuncture-on-chronic-tinnitus-and-its-association-with-auditory-brainstem-response-measures-100633121","NCT07522567","Efficacy of Acupuncture on Chronic Tinnitus and Its Association With Auditory Brainstem Response Measures","Efficacy of Acupuncture on Chronic Tinnitus and Its Association With Auditory Brainstem Response Measures: A Study Protocol for a Matched Case-Control and Self-Controlled Trial","Inclusion Criteria:\n\n1. Aged between 18 and 60 years, inclusive, any sex;\n2. No previous chronic functional or organic diseases, no head injury;\n3. No history of any psychiatric or neurological family genetic disease;\n4. Signed a paper version of the informed consent form and volunteered to participate in this trial.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding women, and those who have a request for childbearing within the last six months;\n2. History of head trauma;\n3. Presence of metallic implants in the body or any other contraindication to ABR testing;\n4. Current participation in any other interventional clinical trial.","60 Years",{"count":479,"type":23},72,[56],"The goal of this clinical trial is to learn if acupuncture works to treat chronic tinnitus in adults. It will also learn about the neurophysiological effects of acupuncture on auditory conduction pathway function. The main questions it aims to answer are:\n\nDoes acupuncture lower tinnitus-related disability and severity, as measured by the Tinnitus Handicap Inventory (THI) and Tinnitus Effects Questionnaire (TEQ)?\n\nWhat changes in auditory brainstem response (ABR) parameters-such as wave I amplitude and wave V latency-occur after acupuncture treatment, and do these changes correlate with clinical improvement?\n\nResearchers will compare ABR parameters and clinical outcomes between chronic tinnitus patients and age- and sex-matched healthy controls to characterize tinnitus-related abnormalities. Additionally, the study will evaluate changes within the patient group before and after a 10-session acupuncture course to assess treatment efficacy and explore its neurophysiological mechanisms.",[29,166,483],"Auditory Brainstem Response",[85,332,485],"auditory brainstem response","2026-04-04",{"date":488,"type":36},"2026-04-13",{"date":490,"type":23},"2026-12-31",{"date":492,"type":23},"2027-07-31",{"name":494,"class":69},"The Third Affiliated hospital of Zhejiang Chinese Medical University",{"id":496,"slug":497,"hasResults":12,"nctId":498,"briefTitle":499,"officialTitle":500,"acronym":501,"eligibilityCriteria":502,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":503,"targetDuration":4,"studyType":24,"phases":504,"briefSummary":505,"conditions":506,"keywords":508,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":509,"lastUpdatePostDateStruct":510,"startDateStruct":512,"completionDateStruct":514,"leadSponsor":516,"locationsCount":44},"100623226","bimodal-electrical-sound-stimulation-and-auditory-training-for-chronic-tonal-tinnitus-100623226","NCT07393880","Bimodal Electrical-Sound Stimulation and Auditory Training for Chronic Tonal Tinnitus","Non-Invasively Re-Training the Tinnitus Brain Using Bimodal Electrical-Sound Stimulation (NITESGON-ADT): Protocol for a Prospective, Double-Blind, Randomised Controlled Trial","NITESGON-ADT","Inclusion Criteria:\n\n* Adults aged 18-80 years\n* Continuous subjective tinnitus for \\>3 months and ≤5 years\n* Predominantly tonal tinnitus (unilateral or bilateral)\n* Screening THI score 28-76\n* Minimum Masking Level (MML) 20-80 dB HL\n* No prior tinnitus neuromodulation treatment\n* Able to comply with eight sessions over four weeks and follow-up assessments\n\nExclusion Criteria:\n\n* Objective tinnitus or predominantly somatic tinnitus\n* Pulsatile tinnitus\n* Evidence of conductive hearing loss (abnormal otoscopy or tympanometry)\n* Pure-tone audiometry exclusions: \\>40 dB HL at any frequency 250 Hz-1 kHz OR \\>80 dB HL at any frequency 2-8 kHz in either ear\n* Hearing aid use initiated within the past 90 days\n* Active implantable medical device (e.g., pacemaker, DBS, cochlear implant)\n* LDL \\\u003C30 dB SL at 500 Hz in either ear\n* Diagnosis of temporomandibular joint disorder or occipital neuralgia\n* Severe anxiety (STAI \\>120\u002F160)\n* Cognitive impairment (MMSE \\\u003C25)\n* Severe depressive symptoms (BDI ≥30)\n* Diagnosis of Menière's disease\n* Current pregnancy\n* Involvement in medicolegal cases\n* History of auditory hallucinations\n* Current prescription of central nervous system drugs likely to alter neuromodulatory function (e.g., noradrenergic, dopaminergic, serotonergic, benzodiazepine, cholinergic, or other psychoactive medications)\n* Currently enrolled in another interventional study",{"count":22,"type":23},[56],"This study tests whether pairing non-invasive stimulation of the greater occipital nerve (NITESGON) with an attentionally demanding auditory frequency discrimination training task reduces tinnitus loudness and tinnitus-related distress. One hundred adults with chronic tonal tinnitus will be randomised to one of four groups in a 2×2 factorial design: real versus sham NITESGON and active versus passive listening during auditory stimulation. Participants complete eight sessions across four weeks, with outcomes assessed at baseline, end of treatment, 28 days post-treatment, and 6 months post-treatment.",[83,29,507],"Chronic Tinnitus",[29],"2026-04-02",{"date":511,"type":36},"2026-04-03",{"date":513,"type":36},"2026-01-30",{"date":515,"type":23},"2029-01-30",{"name":517,"class":69},"University of Dublin, Trinity College",{"id":519,"slug":520,"hasResults":12,"nctId":521,"briefTitle":522,"officialTitle":522,"acronym":4,"eligibilityCriteria":523,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":524,"targetDuration":4,"studyType":24,"phases":526,"briefSummary":527,"conditions":528,"keywords":529,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":532,"lastUpdatePostDateStruct":533,"startDateStruct":535,"completionDateStruct":537,"leadSponsor":539,"locationsCount":44},"100630602","the-effect-of-mild-gain-amplification-on-tinnitus-perception-in-normal-hearing-adults-100630602","NCT07489807","The Effect of Mild-gain Amplification on Tinnitus Perception in Normal Hearing Adults","Inclusion Criteria:\n\n* Daily bothersome tinnitus for at least 3 months (TFI\\>15)\n* Normal hearing (25 dB HL from 125 Hz to 8 kHz)\n* Inexperienced hearing aid user\n\nExclusion Criteria:\n\n* Meniere's disease, Tosclerosis, Stapedectomy, Stapedotomy and Tympanoplasty\n* Objective or pulsatile tinnitus\n* Hearing thresholds \\>25 dB from 125 Hz to 8 kHz",{"count":525,"type":23},15,[56],"This study investigated the effect of mild gain amplification (8dB covering 1 Hz to 8kHz) as tinnitus treatment for participants with normal hearing and compared these effects with an active placebo condition using hearing aids without amplification in a double-blinded crossover study. 12 participants with normal hearing and chronic tinnitus were included in the study. Two different hearing aid treatments were provided for 3 weeks each: mild gain amplification that provided 8dB gain in the frequency range from 1 Hz to 8 kHz and no amplification, acting as placebo. The effect of the two treatments on tinnitus distress was evaluated with the Tinnitus Functional Index (TFI) questionnaire. The effect of the treatment on tinnitus loudness and annoyance were evaluated with a visual analog scale (VAS).",[29],[29,530,531],"Hearing aids","Normal hearing","2026-03-25",{"date":534,"type":36},"2026-03-31",{"date":536,"type":36},"2025-04-01",{"date":538,"type":23},"2027-06-01",{"name":540,"class":69},"Technical University of Denmark",{"id":542,"slug":543,"hasResults":12,"nctId":544,"briefTitle":545,"officialTitle":546,"acronym":4,"eligibilityCriteria":547,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":457,"enrollmentInfo":548,"targetDuration":4,"studyType":24,"phases":550,"briefSummary":551,"conditions":552,"keywords":554,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":556,"startDateStruct":558,"completionDateStruct":560,"leadSponsor":562,"locationsCount":4},"100618621","the-effects-of-conventional-therapy-on-tinnitus-disability-and-quality-of-life-in-patients-with-tinnitus-100618621","NCT07334002","The Effects of Conventional Therapy on Tinnitus, Disability, and Quality of Life in Patients With Tinnitus","A Randomized, Single-blind, Controlled Trial to Evaluate the Effects of Conventional Therapy on Tinnitus, Disability, and Quality of Life in Patients With Tinnitus","Inclusion Criteria:\n\n* Patients with a type A tympanogram in the tympanogram of all cases with normal otological examinations (air-bone gap should not be observed in any case).\n\nExclusion Criteria:\n\n* Patients with a disease that may cause objective tinnitus,\n\n  * Otosclerosis,\n  * Chronic otitis media,\n  * Acoustic tumor,\n  * Meniere's disease,\n  * History of ear surgery or head trauma, and those with neuropsychiatric diseases.\n\nAlso:\n\n* Patients who have had ear surgery,\n* Permanent hearing loss (total),\n* Severe cardiovascular system failure, uncontrolled arrhythmia,\n* Severe renal failure, or liver failure",{"count":549,"type":23},30,[56],"A randomized, single-blind, controlled trial to evaluate the effects of neural therapy on tinnitus severity, disability, and quality of life in patients with tinnitus.\n\nThe study is planned to be conducted between December 2025 and March 2026. The sample size is 30 patients. The number of centers is 1. The study duration is 3 months.",[29,553],"Neural Therapy of Huneke",[553,29],"2026-03-20",{"date":557,"type":36},"2026-03-23",{"date":559,"type":23},"2026-03-01",{"date":561,"type":23},"2026-05-26",{"name":563,"class":69},"Sisli Hamidiye Etfal Training and Research Hospital",{"id":565,"slug":566,"hasResults":12,"nctId":567,"briefTitle":568,"officialTitle":569,"acronym":4,"eligibilityCriteria":570,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":571,"targetDuration":4,"studyType":140,"phases":4,"briefSummary":573,"conditions":574,"keywords":578,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":581,"lastUpdatePostDateStruct":582,"startDateStruct":584,"completionDateStruct":586,"leadSponsor":588,"locationsCount":44},"100628327","cbct-and-audiological-analysis-of-the-tmj-tinnitus-relationship-100628327","NCT07460193","CBCT and Audiological Analysis of the TMJ-Tinnitus Relationship","Investigation of the Interaction Between Temporomandibular Joint and Tinnitus Using CBCT and Audiological Methods: A Prospective Cross-Sectional Study","Inclusion Criteria:\n\n* Patients aged 18 years and older.\n* Patients presenting with otological symptoms such as tinnitus and ear pain.\n* Patients diagnosed with Temporomandibular Disorders (TMD) based on clinical and radiographic examination.\n* Patients who have been referred for CBCT imaging as part of their routine diagnostic process for TMD.\n* Willingness to provide written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Presence of objective tinnitus (e.g., vascular or muscular origin).\n* History of chronic otitis media or other middle ear pathologies that could cause hearing loss or tinnitus.\n* Previous history of temporomandibular joint surgery or major maxillofacial trauma.\n* Presence of systemic metabolic bone diseases or inflammatory rheumatic diseases (e.g., Rheumatoid Arthritis).\n* History of malignancy in the head and neck region.\n* Pregnancy (due to CBCT imaging contraindication).\n* Neurological or psychological disorders that would prevent cooperation during clinical and audiological examinations.",{"count":572,"type":23},50,"The aim of this study is to investigate the relationship between Temporomandibular Disorders (TMD) and subjective tinnitus at both morphological and functional levels. Current literature suggests that somatosensory inputs from the temporomandibular joint (TMJ) and masticatory muscles can modulate auditory pathways, a phenomenon known as Somatosensory Tinnitus. However, the specific role of TMJ bone morphology and critical neighboring structures, such as the Petrotympanic Fissure (PTF), in this interaction remains unclear.\n\nIn this clinical study, patients with tinnitus will undergo a comprehensive evaluation including Cone Beam Computed Tomography (CBCT) to quantitatively analyze condylar morphology and osteoarthritic changes. Additionally, audiological tests will be performed to assess the functional state of the auditory system. This multidisciplinary approach aims to clarify the biological link between TMD and tinnitus, potentially improving diagnostic protocols and highlighting the importance of TMJ stabilization in tinnitus management.",[29,575,576,577],"Temporomandibular Joint Disorders","Somatosensory Tinnitus","Osteoarthritis, Temporomandibular Joint",[29,575,579,580],"Cone-Beam Computed Tomography","Audiometry","2026-03-04",{"date":583,"type":36},"2026-03-10",{"date":585,"type":23},"2026-04-01",{"date":587,"type":23},"2026-07-01",{"name":589,"class":69},"Kutahya Health Sciences University",{"id":591,"slug":592,"hasResults":12,"nctId":593,"briefTitle":594,"officialTitle":595,"acronym":4,"eligibilityCriteria":596,"healthyVolunteers":12,"sex":18,"minAge":597,"maxAge":20,"enrollmentInfo":598,"targetDuration":4,"studyType":24,"phases":599,"briefSummary":600,"conditions":601,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":602,"lastUpdatePostDateStruct":603,"startDateStruct":605,"completionDateStruct":607,"leadSponsor":609,"locationsCount":44},"100626412","navigated-repetitive-tms-for-chronic-tinnitus-100626412","NCT07435298","Navigated Repetitive TMS for Chronic Tinnitus","Neuronavigated Transcranial Magnetic Stimulation As An Adjunctive Treatment For Chronic Tinnitus","Inclusion Criteria:\n\n1. Age 21-80 years old;\n2. Subjective tinnitus severity as per Tinnitus-Visual Analogue Scale of 1\u002F10 and above (in any domain: sound, distress, Quality of Life)\n\nExclusion Criteria:\n\n1. Pregnancy;\n2. Any metal implants inside the body that are contraindications of MRI scan;\n3. Cardiac pacemakers;\n4. Epilepsy with recurrent seizures;\n5. Cognitively impaired patients will be excluded;\n6. Claustrophobia;\n7. Uncontrolled medical conditions including hypertension, diabetes mellitus and unstable angina;\n8. Major depression and a history of psychotic disorders;\n9. Terminal diagnosis with life expectancy \\\u003C=1 year.","21 Years",{"count":572,"type":23},[56],"This study is testing whether a special type of brain stimulation called neuronavigated TMS can help reduce tinnitus (ringing in the ears). 50 people with tinnitus will each receive 20 treatment sessions - 10 real treatments and 10 sham treatments in random order, with a 2-week break between them. Before starting, participants get an MRI brain scan to guide where the stimulation device is placed. Questionnaires of measuring tinnitus severity will be asked four times throughout the study to determine to check the effect of TMS on treating tinnitus.",[29],"2026-02-20",{"date":604,"type":36},"2026-02-27",{"date":606,"type":36},"2025-11-01",{"date":608,"type":23},"2027-10-30",{"name":610,"class":69},"National University Hospital, Singapore",{"id":612,"slug":613,"hasResults":12,"nctId":614,"briefTitle":615,"officialTitle":616,"acronym":617,"eligibilityCriteria":618,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":619,"targetDuration":4,"studyType":24,"phases":620,"briefSummary":621,"conditions":622,"keywords":623,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":627,"lastUpdatePostDateStruct":628,"startDateStruct":630,"completionDateStruct":632,"leadSponsor":633,"locationsCount":44},"100564379","whitby-working-towards-better-healthcare-interventions-for-tinnitus-a-brain-stimulation-study-100564379","NCT06628414","WHITBY: Working Towards Better Healthcare Interventions for Tinnitus: a Brain Stimulation studY","Transcranial Direct Current Stimulation (tDCS) for Tinnitus - Effects of Multiple Treatment Sessions: a Randomised-controlled Pilot Study","WHITBY","Inclusion Criteria:\n\n* Aged 18 or over\n* Suffering from subjective idiopathic tinnitus\n* Sufficient understanding of English to be able to provide informed consent\n* Able to safely undergo tDCS\n\nExclusion Criteria:\n\n* Aged under 18\n* Not suffering from tinnitus or suffering from objective tinnitus\n* Insufficient understanding of English to be able to provide informed consent\n* Unable to safely undergo tDCS as assessed by tDCS Safety Questionnaire\n* Having taken part in a research study in the last 3 months involving invasive procedures or an inconvenience allowance",{"count":189,"type":23},[56],"Tinnitus - the awareness of sound without any outside source - affects around 15% of people and can cause anxiety and depression. Treatment options are limited and do not address tinnitus directly (e.g., reduce its loudness). To do that, we must change brain activity causing tinnitus. Low-dose electrical stimulation, using a technique called transcranial Direct Current Stimulation (tDCS), is a promising approach. The technique is safe and easy to administer. Several small studies have tested tDCS for tinnitus showing some benefits.\n\nTo assess whether these benefits will generalise to other patients, we need to conduct a randomised controlled trial - a large, rigorously controlled experiment based on prior agreed procedures. Clinical trials are expensive and time-consuming to run and thus require meticulous pilot work to establish the most effective treatment regimens and the most sensitive measures of treatment outcome. The current study aims to provide such pilot information for a clinical trial of tDCS treatment of tinnitus. Using a total of 40 patients, we will establish how to best to administer tDCS and measure resulting changes in tinnitus perception and associated brain activity.\n\nThe current study is a crucial first step towards determining whether or not tDCS can effectively treat tinnitus.",[29],[85,624,625,626],"brain stimulation","neuromodulation","transcranial direct current stimulation","2026-02-09",{"date":629,"type":36},"2026-02-12",{"date":631,"type":36},"2024-12-01",{"date":38,"type":23},{"name":634,"class":69},"University of Nottingham",{"id":636,"slug":637,"hasResults":12,"nctId":638,"briefTitle":639,"officialTitle":640,"acronym":641,"eligibilityCriteria":642,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":457,"enrollmentInfo":643,"targetDuration":4,"studyType":24,"phases":644,"briefSummary":645,"conditions":646,"keywords":648,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":657,"lastUpdatePostDateStruct":658,"startDateStruct":660,"completionDateStruct":662,"leadSponsor":663,"locationsCount":44},"100571299","tinnitus-and-treatment-with-umpea-lut-100571299","NCT06718452","Tinnitus and Treatment With umPEA-LUT","Treatment of Tinnitus Targeting Neuroinflammation. umPEALUT as Possible Option","TiniPEA","Inclusion Criteria:\n\n\\- Patients with tinnitus not under treatment at least for 30 days\n\nExclusion Criteria:\n\n* Stroke in the last year\n* Uncontrolled diabetes,\n* Uncontrolled hypertension,\n* Severe psychiatric disorders,\n* Severe cognitive decline,\n* Previous surgery of the brain or audio-vestibular nerves",{"count":22,"type":23},[56],"Tinnitus can have different causes. From a peripheral point of view, the sensation of hearing a not present sound can be indicative of damage in the cells of the cochlea. Damage at this level can arise from traumatic, vascular, toxic origins or be caused by systemic pathologies. However, all the previous causes have a common denominator, the presence of reactive oxygen species (ROS), in the cochlea which determines the damage and the consequent death of the hair cells into the ear. The sound (tinnitus) that the patient perceives is generated by the spontaneous movement of the cilia of the hair cells; this phenomenon arises when these cells begin to be damaged.\n\nTinnitus can be also caused by a retrocochlear disorder such as damage of the auditory nerve (inflammatory and tumor cause). In case of an inflammatory origin, the factors released during inflammation can locally damage the nerves and spread into the cochlea destroying the hair cells.\n\nTinnitus can also originate from damage in the central auditory pathway. In this case, the problem persistent. It is important to keep in mind that although initially the tinnitus may originate from a damage inside the cochlea, after 6 months of persistence chronicizes causing an activation (without stimulus) of the upper auditory areas. This zone of \"hypersensitivity\" is therefore responsible for chronic tinnitus.\n\nIn addition to the overmentioned medical causes, tinnitus can also be sign of psychiatric\u002Fpsychological disorders, in those cases in whom there is an involvement of the hypothalamus, as showed by neuropsychological studies. Tinnitus can be temporary and disappear spontaneously or, in the most of cases, be persistent and extremely annoying\u002Fstressful for the patient. At night in particular, in the absence of noise, the patient suffers more the presence of this ghost sound, which in some occasions prevents sleep. Insomnia negatively impacts on tinnitus increasing its duration and intensity, thus establishing a perpetual cycle of stress into the brain. The latter phenomenon worses and chronicizes the symptom .\n\nStress causes inflammation with ROS increase, which can affect both the peripheral and central auditory pathways. Recently, it has been shown that tinnitus can be a symptom of neuro-inflammatory pathologies such as, for example, Multiple Sclerosis.\n\nThe effects of inflammation on the hair cells are identifiable only through electrophysiological studies or from the temporal bone.\n\nKeeping on mind inflammation and neuro-inflammation and considering the exchange between cerebrospinal fluid and perilymph , we speculate that the use of a molecule capable of reducing inflammation and modulating the action of mast cells and microglia, could be an effective tool to resolve tinnitus; moreover, thanks to its powerful action at the level of neuro-inflammation, it could reduce the hyper-activity in the upper auditory tracts, thus reducing\u002Fabolishing noise.\n\numPeaLut combines palmitoylethanolamide, which modulates the activity of mast cells, macrophages and microglia and luteolin, a bioflanoid extracted from fruits with anti-oxidant properties, able to improve microcirculation. Because the alterations of the ear microcirculation can be an additional cause of tinnitus, we believe that luteolin content can be an ulterior benefit.\n\nAlthough various attempts have been made to use a mono-molecule, recent studies have shown that combination of several elements could reduce tinnitus ; PeaLut, in its ultra-micronized form with high bioavailability, could be the perfect solution.\n\nThis study aims at evaluating the efficacy of umPEALUT as a therapeutic treatment of tinnitus in a sample of adults.",[29,647],"Neuroinflammation",[29,647,649,650,651,652,653,654,655,656],"Palmitoyetanolamide","Luteolin","Ultramicronized","Vascular","Central","Peripheral","Auditory cortex","Inner ear","2026-02-03",{"date":659,"type":36},"2026-02-06",{"date":661,"type":23},"2026-04-20",{"date":490,"type":23},{"name":664,"class":69},"University of Campania Luigi Vanvitelli",{"id":666,"slug":667,"hasResults":12,"nctId":668,"briefTitle":669,"officialTitle":669,"acronym":4,"eligibilityCriteria":670,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":671,"targetDuration":4,"studyType":24,"phases":672,"briefSummary":674,"conditions":675,"keywords":676,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":681,"startDateStruct":683,"completionDateStruct":685,"leadSponsor":687,"locationsCount":44},"100377303","early-phase-1-an-fmri-investigation-of-the-effects-of-iv-lidocaine-on-tinnitus-100377303","NCT04192773","An fMRI Investigation of the Effects of IV Lidocaine on Tinnitus","Inclusion Criteria:\n\n-Age ≥ 18\n\n* Ability to provide informed consent\n* English speaker\n* Falls under one of the four groups a. Normal Hearing without Tinnitus (NH\u002FT-) i. Normal Hearing as defined as pure tone thresholds of 25 dB or less across all tested frequencies ii. Subjective confirmation of lack of tinnitus\\* 1. Never or rarely b. Normal Hearing with Tinnitus (NH\u002FT+) i. Normal Hearing Normal Hearing as defined as pure tone thresholds of 25 dB or less across all tested frequencies ii. Subjective confirmation of tinnitus\\* 1. Often, always c. Unilateral hearing loss and ipsilateral unilateral tinnitus (uHL\u002FuT+) i. Unilateral hearing loss as defined by pure tone thresholds of 50 dB or greater across 3 frequencies in the bad ear and 25 dB or less in good ear ii. Subjective confirmation of tinnitus in the good ear\\* 1. Often, always d. Bilateral hearing loss and bilateral tinnitus (bHL\u002FbT+) i. Bilateral hearing loss as defined by pure tone thresholds of 50 dB or greater across 3 frequencies in both ears ii. Subjective confirmation of tinnitus in both ears\\*\n\n  1. Often, always\n\n     * Tinnitus will be confirmed via Likert-scale: Never - Rarely - Sometimes - Often - Always\n\nExclusion Criteria:\n\n* Currently undergoing tinnitus treatment with other pharmacologic agents\n\n  a. Patients may be eligible if they complete a 60 day washout period from pharmacologic agents treating tinnitus\n* Inability to tolerate fMRI or other contraindications of fMRI including claustrophobia or presence of ferromagnetic objects in the body that cannot be removed.\n* Contraindications to IV lidocaine administration such known allergy to lidocaine\n* History of myocardial infarction or cardiac arrhythmias including Wolff-Parkinson-White, severe sinoatrial, atrioventricular or intraventricular heart block in the absence of a pacemaker\n* History of seizure disorder\n* Resting BP of \\\u003C100\u002F50\n* Currently taking antiarrhythmics\n* Have taken antibiotics within 48 hours of infusion\n* Known hepatic failure\n* Pregnant or lactating women\n* Patient with other neurological or psychiatric disorders, such as stroke, brain tumor, schizophrenia, bipolar disorder.\n* Patients who cannot fill out the questionnaires",{"count":189,"type":23},[673],"EARLY_PHASE1","This is an exploratory pilot open-label study to identify the signal changes on fMRI of patients with tinnitus and with temporary suppression of the tinnitus with IV lidocaine. Patients will include those with hearing loss (both unilateral and bilateral) and tinnitus, subjects with normal hearing and tinnitus, and control subjects with normal hearing and no tinnitus. Eligible subjects will have functional and subjective data collected at baseline, receive an IV lidocaine infusion, and have functional and subjective data collected post-infusion for comparison and identification of involved neural networks.",[29],[85,677,678,679,680],"normal control","hearing loss","IV lidocaine","fMRI",{"date":682,"type":36},"2025-12-02",{"date":684,"type":36},"2021-04-28",{"date":686,"type":23},"2027-12-31",{"name":688,"class":69},"D. Bradley Welling, MD, PhD"]